SARS treatment: who will lead the way forward?
Larkin
Marilynn
M
D015195:Drug Design; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy*
D012254:Ribavirin; D007372:Interferons